Onc Club | Articles

DREAMSeq Trial Clarifies Treatment Sequencing in BRAF V600–Mutant Melanoma

November 8th 2022

Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.

Pembrolizumab Plus Cabozantinib Improves ORR in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

November 8th 2022

A doublet regimen comprised of pembrolizumab and cabozantinib elicited encouraging responses in patients with recurrent metastatic head and neck squamous cell carcinoma, meeting the primary end point of a phase 2 trial.

Pafolacianine Detects Microlesions in Folate Receptor–Positive Ovarian Cancer

September 27th 2022

Pafolacianine used during ovarian cancer surgery identified additional tumors that were not detected with conventional means and not otherwise planned for resection, according to results from a phase 3 study recently published in the Journal of Clinical Oncology.

Poziotinib Elicits Encouraging, Insertion Location–Specific Response Rates in EGFR Exon 20–Mutant NSCLC

August 4th 2022

Yasir Y. Elamin, MD, explained the rationale, design, and key findings of a phase 2 study evaluating poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer.

Armstrong Highlights Outcomes of Final Survival Analysis of Enzalutamide Plus ADT in mHSPC

May 2nd 2022

Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.

COVID-19 Booster Yields Responses After Failure of Initial Vaccine Doses in Prior HCT or CAR T-Cell Therapy Recipients

April 29th 2022

The administration of a third dose of a SARS-CoV-2 mRNA vaccine yielded seroconversion responses in patients treated with hematopoietic cell transplantation or cellular therapy following initial failure of seroconversion after the first 2 vaccine doses.

Enzalutamide Plus ADT Demonstrates Significant Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

April 28th 2022

Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.

Resistance to Noncovalent BTK Inhibitors Raises Questions Around Impact of Mutations in CLL

April 14th 2022

A small proportion of a subset of patients with chronic lymphocytic leukemia acquired mechanisms of genetic resistance to the novel noncovalent BTK inhibitor pirtobrutinib, according to results from a genomic analysis of patients in the phase 1/2 BRUIN trial.

Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination

November 22nd 2021

Muhammad Bilal Abid, MD, discusses immune-compromising factors that are indigenous to CAR T-cell recipients, the immunogenic potential of different COVID-19 vaccines, determinants of response, and the potential need for booster strategies.

Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma, as Efforts Shift to Target Other FGFR Alterations

November 9th 2021

Sameek Roychowdhury, MD, PhD, discusses the efficacy and safety data reported with infigratinib in FGFR2-positive cholangiocarcinoma, nuances to treatment with the agent, and ongoing research efforts to further improve outcomes in this population.

Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma

November 1st 2021

The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.

Cancer Screening Tests Rebound Following First Peak of COVID-19 Pandemic

August 10th 2021

After a dramatic decrease during the first peak of the COVID-19 pandemic, a substantial increase in cancer screening procedures during more recent time periods has been reported, according to data from a research letter published in Cancer Cell.

COVID-19 Vaccination Induces High Seroconversion Rates in Patients With Cancer, But Novel Strategies Needed for Select Subsets

July 8th 2021

Balazs Halmos, MD, MS, discusses a study examining the effectiveness of COVID-19 vaccination in patients with cancer and identified important areas for future research.

Landgren Lauds Promise of Carfilzomib Quadruplet Regimen in Newly Diagnosed Myeloma

June 16th 2021

C. Ola Landgren, MD, PhD, discusses important research efforts that led to the launch of the phase 2 MANHATTAN trial, the results achieved with the weekly carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, and the potential for this approach irrespective of transplant eligibility status.

Weekly Carfilzomib Quadruplet Induces High Rates of MRD Negativity, PFS in Newly Diagnosed Myeloma

May 11th 2021

The quadruplet combination comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab was linked with high rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma.

Whole-Genome Sequencing Identifies 2 Distinct Myeloma Precursor Conditions

May 3rd 2021

Whole-genome sequencing has the potential to accurately differentiate between stable and progressive precursor conditions to multiple myeloma in low disease burden clinical states and the use of this technology in the clinic may result in a significant shift in the management of these patients.

Bringing Individualized Care to Patients With Breast and Ovarian Cancers in the Caribbean

April 26th 2021

Current breast cancer screening practices in the Caribbean exclude the majority of the younger patient population, thereby leaving many cases of breast cancer undiagnosed.

Abu-Zeinah Shares Next Steps for Research With Interferon-Alpha in Polycythemia Vera

April 9th 2021

Now that interferon-alpha has been shown to prolong survival in patients with polycythemia vera, it is important that investigative efforts focus on developing a better understanding on the biology of the disease and the mechanisms by which the agent actually improves outcomes.

1 in 7 Caribbean Adults With Breast or Ovarian Cancers Have Actionable Pathogenic Variants

March 10th 2021

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

Interferon-Alpha Improves MFS and OS Over Standard Approaches in Polycythemia Vera

March 9th 2021

Interferon-alpha has been shown to significantly improve both myelofibrosis-free survival and overall survival over hydroxyurea and phlebotomy only in patients with polycythemia vera.